Portal de Periódicos da CAPES

Plasmablastic Posttransplant Lymphoma

2012; Wolters Kluwer; Volume: 93; Issue: 5 Linguagem: Inglês

10.1097/tp.0b013e318242162d

1534-6080

Heiner Zimmermann, Ilske Oschlies, Susanne Fink, Christiane Pott, Hans H. Neumayer, H. Lehmkuhl, Ingeborg A. Hauser, Martin Dreyling, Michael Kneba, Barbara C. Gärtner, Ioannis Anagnostopoulos, Hanno Riess, Wolfram Klapper, Ralf Ulrich Trappe,

Eosinophilic Disorders and Syndromes

Background. Plasmablastic posttransplant lymphoma is a rare subtype of monomorphic B-cell posttransplant lymphoproliferative disorder (PTLD). There is little published clinical data to guide treatment. Methods. The German prospective PTLD registry D2006–2012 records baseline features, treatment, and outcome of rare PTLD subtypes in adults after solid organ transplantation. Treatment is at the discretion of the local physician. Clinical data on the patients in the registry is collected before, during, and at least 4 weeks, 6 months, 12 and 24 months after treatment. Results. Eight cases of plasmablastic posttransplant lymphoma were reported to the registry until 2011. The majority occurred as late PTLD in male heart transplant recipients. Extranodal manifestations were common in stage I and in stage IV disease. Histological Epstein-Barr virus (EBV) association was confirmed in five of eight cases. MYC/IGH rearrangement was present in two of six patients examined. Although five of eight patients died from early disease progression, we observed that long-term survival can be achieved in localized (2/3) and in disseminated disease (1/5) by immunosuppression reduction (IR) followed by immediate systemic chemotherapy. However, all patients with cytogenetic aberrations and patients with non-EBV-associated PTLD were refractory to IR and to chemotherapy. Chemotherapy parallel to IR was associated with a high rate of infectious complications. Conclusions. In this series, IR and local therapy were not sufficient to treat plasmablastic posttransplant lymphoma even in localized disease whereas IR and systemic chemotherapy (CHOP-21) could achieve lasting complete remissions. Cytogenetic aberrations and lack of EBV association were linked with poor outcome.